Russell Investments Group Ltd. Buys 4,212 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Russell Investments Group Ltd. lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 17.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 28,115 shares of the medical research company's stock after acquiring an additional 4,212 shares during the quarter. Russell Investments Group Ltd. owned 0.05% of Charles River Laboratories International worth $6,646,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in CRL. VisionPoint Advisory Group LLC lifted its stake in Charles River Laboratories International by 105.7% during the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company's stock worth $28,000 after purchasing an additional 74 shares in the last quarter. Headlands Technologies LLC purchased a new position in Charles River Laboratories International during the 3rd quarter valued at about $37,000. Operose Advisors LLC purchased a new position in Charles River Laboratories International during the 3rd quarter valued at about $42,000. Venturi Wealth Management LLC grew its position in Charles River Laboratories International by 74.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company's stock valued at $51,000 after acquiring an additional 112 shares in the last quarter. Finally, GAMMA Investing LLC purchased a new stake in Charles River Laboratories International during the fourth quarter worth about $62,000. Hedge funds and other institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Stock Performance

NYSE:CRL traded down $5.18 during midday trading on Thursday, reaching $230.11. The stock had a trading volume of 1,004,419 shares, compared to its average volume of 548,995. The stock has a market cap of $11.85 billion, a P/E ratio of 24.98, a P/E/G ratio of 1.83 and a beta of 1.44. The company has a quick ratio of 1.16, a current ratio of 1.52 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a 12-month low of $161.65 and a 12-month high of $275.00. The firm has a fifty day simple moving average of $250.70 and a two-hundred day simple moving average of $225.27.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.39 by $0.07. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business's revenue was down 7.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.98 earnings per share. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on CRL. Citigroup raised their price objective on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the company a "neutral" rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. boosted their target price on Charles River Laboratories International from $270.00 to $280.00 and gave the stock an "overweight" rating in a research note on Thursday, February 15th. Argus boosted their target price on shares of Charles River Laboratories International from $240.00 to $290.00 and gave the stock a "buy" rating in a research note on Monday, March 18th. Evercore ISI raised their price objective on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the stock an "outperform" rating in a report on Thursday, February 15th. Finally, Guggenheim lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating in a report on Thursday, February 15th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $253.23.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, VP William D. Barbo sold 4,050 shares of the business's stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the sale, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP William D. Barbo sold 4,050 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the completion of the sale, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Shannon M. Parisotto sold 5,882 shares of the business's stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $241.20, for a total value of $1,418,738.40. Following the sale, the executive vice president now directly owns 2,596 shares in the company, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders have sold a total of 14,932 shares of company stock worth $3,693,663 over the last three months. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).